H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio have announced the availability of the Lumipulse G sTREM2 assay for their fully automated LUMIPULSE® G immunoassay analyzers. The chemiluminescent enzyme immunoassay (CLEIA) is designated for Research Use Only (RUO) and enables quantitative measurement of soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) in human cerebrospinal fluid and blood samples within 35 minutes.
Advancing Neuroinflammation Research
sTREM2 represents a promising biomarker of microglial activation, providing researchers with critical insights into neuroinflammation processes linked to Alzheimer's disease and other neurodegenerative conditions. The biomarker offers valuable capabilities for capturing inflammatory response dynamics and monitoring inflammatory modulators in neurological research settings.
"By adding sTREM2 to our neuro portfolio, we're enabling a more comprehensive view of neurological disease mechanisms," said Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. "sTREM2 complements established biomarkers like GFAP, NfL, and pTau by adding essential insight into neuroinflammation - offering a more complete picture of the disease on a single platform."
Expanding Diagnostic Portfolio
The new sTREM2 assay strengthens Fujirebio's growing portfolio of neurological biomarkers, which already includes glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and phosphorylated tau (pTau). This expansion reinforces the company's position in advancing neuro biomarker research tools and diagnostics.
The automated nature of the assay on the LUMIPULSE G analyzers provides researchers with convenient, accurate, and robust measurement capabilities for sTREM2. These analyzers are already widely deployed for routine neurological disease testing worldwide and meet established quality, throughput, and regulatory requirements.
Clinical Research Applications
The availability of this microglial biomarker test enables researchers and clinical research professionals to further investigate the potential clinical utility of sTREM2 in neurological disease research. The fully automated random access capability of the LUMIPULSE G platform supports efficient workflow integration for research laboratories studying neurodegenerative diseases.
Fujirebio brings over 50 years of experience in developing, producing, and commercializing in vitro diagnostic products globally. The company pioneered cerebrospinal fluid biomarker development and marketing under the Innogenetics brand over 25 years ago, establishing its leadership in neurological diagnostic tools. The company continues to partner with organizations and clinical experts worldwide to develop pathways for earlier, more accessible, and comprehensive neurodegenerative diagnostic approaches.
